[Nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment].
There have so far been few reports of the pharmacokinetics of oxaliplatin in patients with renal impairment. This report describes the nephrotoxicity induced by repeated cycles of oxaliplatin in a Japanese colorectal cancer patient with moderate renal impairment(creatinine clearance(Ccr): 20-30mL/min). The patient was a 77-year-old male who had chronic renal impairment and received the modified FOLFOX6 repeated every 2 weeks. In cycle 8, the blood concentration of oxaliplatin(66 mg/m2)was measured as the platinum level to confirm the patient's safety. The serum ultrafiltrate concentrations of platinum were 800, 1, 000, 300, <200, and <200 ng/mLat 1, 2, 3 hr, 1 week, and 2 weeks after the start of infusion, respectively, which were closely comparable with the population pharmacokinetic data in Japanese patients with normal renal function. On the other hand, the serum creatinine value was gradually increased after cycle 6, resulting in a decrease of Ccr. The mean Ccr during day 1-59 and day 240-299were significantly different at 26. 5+/-2. 8(mean+/-SD)and 9. 6+/-1. 9mL/min, respectively. Consequently, the chemotherapy showed a complete response after 10 cycles, but the patient got dialysis on day 311. In conclusion, the repeated cycles of oxaliplatin cumulatively damaged the renal function in a Japanese patient with a moderate renal impairment.
Kawazoe
Hitoshi
H
Division of Pharmacy, Ehime University Hospital.
Kawazoe
Hitoshi
H
Sugishita
Hiroki
H
Watanabe
Shinichi
S
Tanaka
Akihiro
A
Morioka
Jyunko
J
Suemaru
Katsuya
K
Watanabe
Yuji
Y
Kawachi
Kanji
K
Araki
Hiroaki
H
D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D044466:Asian People; D015179:Colorectal Neoplasms / Q000097:blood / Q000150:complications / Q000188:drug therapy*; D003401:Creatine / Q000097:blood; D005472:Fluorouracil / Q000627:therapeutic use; D006801:Humans; D007674:Kidney Diseases / Q000097:blood / Q000150:complications / Q000503:physiopathology*; D002955:Leucovorin / Q000627:therapeutic use; D008297:Male; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood / Q000627:therapeutic use; D000077150:Oxaliplatin; D006435:Renal Dialysis
D009944:Organoplatinum Compounds; D000077150:Oxaliplatin; D003401:Creatine; D002955:Leucovorin; D005472:Fluorouracil